

Agenda



- Highlights and Business Update
- Financial Performance H1 2019
- Outlook 2019
- Q&A



Dr. Joachim Kuhn (CEO) Stefan Döhmen (CFO)



Dynamic growth in H1 2019



Strong growth performance: Revenue +26% to 31.3 Mio. EUR

Excellent progress in "Services": Revenue +69%, broadened customer base

Cost ratios: Power20+ program bears fruits, EBITDA margin increases from 5% to 13%


Guidance: Expected at upper end of initial guidance, c. 20% revenue growth and 11-14% EBITDA margin




Excellent growth in Business Line "Services" ...





Total Revenue: Group



Total Revenue by business line








...driven by strong increase in Container Rental




Revenue Growth in Business Lines "Services" in H1 2019



EBITDA increased by 215%



P&L



Power 20+ Program is evolving well



COMMENTS

- Focus on profitable revenue growth
- **2. Focus** on continuous cost efficiency

Examples

- Reduction of logistic costs
- Reduction in energy costs
- Optimized production
- Improved purchasing


> 60 individual projects












No major changes in the balance sheet



BALANCE SHEET



Cash Flow Summary



COMMENTS

in EUR Mio.	H1/19	H1/18
Operating cash flow before changes in Working Capital	1.4	-0.3
Operating cash flow	0.3	-3.9
Investing cash flow *net of dissolution of EUR 9 Mio. short-term investments	-3.7	-4.4*
thereof payments for investments in property, plant and equipment	-3.5	-13.4
Financing cash flow	-1.1	8.4
Net change in cash	-4.4	0.2


- Operating CF before WC positive, clear upward trend
- OCF break even
- Investing CF reflecting softer investments after a heavy investment period following the IPO, H1 2018 influenced by 9 Mio. EUR dissolution of short-term investments (IPO funds)

Continued comfortable liquidity position




LIQUIDITY DEVELOPMENT, 12/2018 – 06/2019

In EUR Mio.







Key drivers intact



Switch to Biopharmaceuticals Share of drug classes on global Top 100 drugs, in 2018 **Biologics** 53% Protein-based Conventional 47% Molecules Small Molecules We have the right tools to secure TempChains!

Energy Efficiency/Climate Crisis





About 50% of thermal energy can be saved with currently available technology incl. VIP

Thank you for your attention!

Lurrinansa Cargo

va-Q-tec AG

Alfred-Nobel-Straße 33 97080 Würzburg

Tel.: +49 931 35942-1616 Fax: +49 931 35942-0

IR@va-Q-tec.com

JYP50294VQ

va-Q-tainer

TICKER

Symbol: VQT

Bloomberg: VQT:GY Reuters: VQTG:DE ISIN: DE0006636681

WKN: 663668

Consolidated income statement



kEUR	H1 2019	H1 2018	
Revenues	31.263	24.860	
Change in inventories	-537	986	
Work performed by the company and capitalised	1.517	3.326	
Other operating income	2.255	1.787	
Total Income	34.498	30.959	
Cost of materials and services	-13.839	-14.192	
Gross profit	20.659	16.767	
Personnel expenses	-10.872	-9.843	
Other operating expenses	-5.419	-5.537	
EBITDA	4.368	1.387	
Depreciation, amortization and impairment losses	-5.938	-4.589	
Earnings before interest and tax (EBIT)	-1.570	-3.202	
Result from equity accounted investments	-68	-51	
Result from fair value valuation of investments	1.771	-	
Finance Income	8	11	
Finance expenses	-538	-375	
Net financial result	-530	-364	
Earnings before tax (EBT)	-397	-3.617	
Income tax	-383	290	
Net income	-780	-3.327	

Consolidated income statement



keur	H1 2019	H1 2018
Consolidated net income attributable to owners of va-Q-tec AG	-780	-3.327
Earnings per share – basic /diluted in EUR	-0,06	-0,25
Consolidated statement of compehensive income		
kEUR		
Net Income	-780	-3.327
Consolidated other comprehensive income		
Currency translation differences	-1	-
Total other comprehensive income that will be reclassified to profit or loss	-1	-
Consolidated total comprehensive income	-781	-3.327
Consolidated total comprehensive income attributable to owners of va-Q-tec AG	-781	-3.327

Consolidated statement of financial position



Assets	H1 2019	FY 2018	
kEUR			
Non-current assets			
Intangible assets	2.531	2.437	
Property, plant and equipment	69.799	69.390	
Investment property	1.614	1.614	
Contract assets	168	157	
Equity accounted interests	_	580	
Financial assets	2.471	184	
Other non-financial assets	619	647	
Deferred tax assets	2.645	2.961	
Total non-current assets	79.847	77.970	
Current assets			
Inventories	10.670	10.924	
Trade receivables	8.475	7.557	
Other financial assets			
- of which deposits (6 - 12 months): 0 (previous year: 9.000)	688	334	
Current tax assets	67	135	
Other non-financial assets	1.170	1.073	
Cash and cash equivalents	7.717	12.154	
Total current assets	28.787	32.177	
Total assets	108.634	110.147	

Consolidated statement of financial position



Equity and liabilities	H1 2019	FY 2018	
keur			
Equity			
Issued share capital	13.090	13.090	
Treasury shares	-54	-54	
Additional paid-in capital	46.158	46.158	
Consolidated total other comprehensive income	-40	-39	
Retained earnings	-14.675	-13.895	
Total equity	44.479	45.260	
Non-current liabilities			
Provisions	127	79	
Bank borrowings	23.415	24.732	
Other financial liabilities	6.370	6.814	
Other non-financial liabilities	8.548	9.310	
Total non-current liabilities	38.460	40.935	
Current liabilities			
Provisions	81	62	
Bank borrowings	11.088	9.400	
Other financial liabilities	5.491	4.873	
Liabilities from contracts with customers	35	19	
Trade payables	3.962	4.594	
Tax liabilities	57	79	
Other non-financial liabilities	4.981	4.925	
Total current liabilities	25.695	23.952	
Total Equity and liabilities	108.634	110.147	

Consolidated statement of cash flow



kEUR	H1 2019	H1 2018
Cash flow from operating activities		
Net income	-780	-3.327
Current income taxes recognized income statement	66	-1
Income taxes paid	-65	-
Net finance costs recognised income statement	530	364
Interest received	-	2
Interest paid	-508	-364
Depreciation on capitalized contract cost	9	30
Non-cash losses from equity accounted investments	68	51
Non-cash gain from fair value valuation of investments	-1.771	-
Depreciation, amortisation and impairment losses	5.889	4.589
Gain/loss from disposal of non-current assets	-254	-52
Change in other assets	-672	-182
Change in other liabilities	67	384
Change in provisions	66	-28
Other non-cash expenses or income	-1.234	-1.756
Cash flow from operating activities before working capital		
changes	1.411	-290
Change in inventories	415	-2.377
Change in trade receivables	-908	2
Change in trade payables	590	-1.225
Net cash flow from operating activities	328	-3.890

Consolidated statement of cash flow



kEUR	H1 2019	H1 2018
Cash flow from investing activities		
Payments for investment in intangible assets	-519	-206
Payments for investments in property, plant and equipment	366	225
Proceeds from disposal of property, plant and equipment	-3.505	-13.389
Proceeds from the release from of short-term deposits	-	9.000
Payments for investments in Contract Assets	-19	-
Net cash flow from investing activities	-3.677	-4.370
Cash flow from financing activities		
Proceeds from bank loans	5.655	9.243
Repayments of bank loans	-5.287	-1.689
Proceeds from sale-and-finance-leaseback transactions	-	2.786
Payments for leases liabilities	-1.453	-1.929
Net cash flow from financing activities	-1.085	9.411
Change in cash and cash equivalents before exchange rate effects	-4.434	151
Effect of exchange rate changes on cash and cash equivalents	-3	47
Net change in cash and cash equivalents	-4.437	198
Cash and cash equivalents at start of period	12.154	5.201
Cash and cash equivalents at end of period	7.717	5.399